Gain Therapeutics Stock Number Of Shares Shorted

GANX Stock

USD 1.86 0.12 6.90%

Gain Therapeutics fundamentals help investors to digest information that contributes to Gain Therapeutics' financial success or failures. It also enables traders to predict the movement of Gain Stock. The fundamental analysis module provides a way to measure Gain Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gain Therapeutics stock.

Total Current Liabilities Other Current Liab

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gain Therapeutics Company Number Of Shares Shorted Analysis

Gain Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Shares Shorted

Shorted by Public

+

by Institutions

More About Number Of Shares Shorted | All Equity Analysis

Current Gain Therapeutics Number Of Shares Shorted

718.74 K

Most of Gain Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gain Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Gain Number Of Shares Shorted Driver Correlations

Understanding the fundamental principles of building solid financial models for Gain Therapeutics is extremely important. It helps to project a fair market value of Gain Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Gain Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gain Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gain Therapeutics' interrelated accounts and indicators.

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Long Term Debt	Short Long Term Debt	Intangible Assets	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.72	0.71	0.67	0.99	0.91	0.48	0.98	0.97	0.22	-0.92	0.87	0.97	0.89	0.97	0.99	-0.77	0.91	-0.16	-0.34	-0.34
Retained Earnings	-0.72		-0.82	-0.97	-0.67	-0.9	0.2	-0.71	-0.65	-0.71	0.49	-0.91	-0.66	-0.91	-0.65	-0.74	0.99	-0.92	0.58	0.81	0.81
Accounts Payable	0.71	-0.82		0.7	0.68	0.85	-0.1	0.71	0.65	0.26	-0.42	0.94	0.66	0.9	0.63	0.67	-0.83	0.82	-0.15	-0.43	-0.43
Net Receivables	0.67	-0.97	0.7		0.63	0.83	-0.14	0.66	0.61	0.83	-0.52	0.84	0.62	0.86	0.61	0.7	-0.93	0.85	-0.73	-0.9	-0.9
Total Current Assets	0.99	-0.67	0.68	0.63		0.86	0.53	1.0	1.0	0.16	-0.94	0.83	1.0	0.85	0.99	0.99	-0.73	0.88	-0.17	-0.32	-0.32
Common Stock	0.91	-0.9	0.85	0.83	0.86		0.11	0.87	0.83	0.44	-0.71	0.96	0.83	0.97	0.82	0.9	-0.92	0.98	-0.25	-0.51	-0.51
Property Plant Equipment	0.48	0.2	-0.1	-0.14	0.53	0.11		0.48	0.53	-0.34	-0.73	0.07	0.53	0.13	0.56	0.45	0.16	0.08	0.2	0.31	0.31
Total Assets	0.98	-0.71	0.71	0.66	1.0	0.87	0.48		1.0	0.19	-0.92	0.85	1.0	0.87	0.99	0.99	-0.77	0.9	-0.22	-0.38	-0.38
Total Stockholder Equity	0.97	-0.65	0.65	0.61	1.0	0.83	0.53	1.0		0.14	-0.94	0.8	1.0	0.82	1.0	0.98	-0.72	0.86	-0.2	-0.33	-0.33
Current Deferred Revenue	0.22	-0.71	0.26	0.83	0.16	0.44	-0.34	0.19	0.14		-0.16	0.43	0.15	0.48	0.16	0.28	-0.62	0.45	-0.86	-0.91	-0.91
Net Debt	-0.92	0.49	-0.42	-0.52	-0.94	-0.71	-0.73	-0.92	-0.94	-0.16		-0.65	-0.94	-0.7	-0.96	-0.93	0.54	-0.72	0.21	0.26	0.26
Total Liab	0.87	-0.91	0.94	0.84	0.83	0.96	0.07	0.85	0.8	0.43	-0.65		0.81	0.99	0.8	0.85	-0.92	0.94	-0.3	-0.56	-0.56
Net Invested Capital	0.97	-0.66	0.66	0.62	1.0	0.83	0.53	1.0	1.0	0.15	-0.94	0.81		0.83	1.0	0.98	-0.73	0.87	-0.2	-0.34	-0.34
Capital Stock	0.89	-0.91	0.9	0.86	0.85	0.97	0.13	0.87	0.82	0.48	-0.7	0.99	0.83		0.82	0.87	-0.91	0.94	-0.34	-0.58	-0.58
Net Working Capital	0.97	-0.65	0.63	0.61	0.99	0.82	0.56	0.99	1.0	0.16	-0.96	0.8	1.0	0.82		0.98	-0.71	0.85	-0.21	-0.34	-0.34
Short Term Debt	0.99	-0.74	0.67	0.7	0.99	0.9	0.45	0.99	0.98	0.28	-0.93	0.85	0.98	0.87	0.98		-0.8	0.92	-0.26	-0.42	-0.42
Long Term Debt	-0.77	0.99	-0.83	-0.93	-0.73	-0.92	0.16	-0.77	-0.72	-0.62	0.54	-0.92	-0.73	-0.91	-0.71	-0.8		-0.96	0.51	0.75	0.75
Short Long Term Debt	0.91	-0.92	0.82	0.85	0.88	0.98	0.08	0.9	0.86	0.45	-0.72	0.94	0.87	0.94	0.85	0.92	-0.96		-0.34	-0.58	-0.58
Intangible Assets	-0.16	0.58	-0.15	-0.73	-0.17	-0.25	0.2	-0.22	-0.2	-0.86	0.21	-0.3	-0.2	-0.34	-0.21	-0.26	0.51	-0.34		0.94	0.94
Long Term Debt Total	-0.34	0.81	-0.43	-0.9	-0.32	-0.51	0.31	-0.38	-0.33	-0.91	0.26	-0.56	-0.34	-0.58	-0.34	-0.42	0.75	-0.58	0.94		1.0
Capital Surpluse	-0.34	0.81	-0.43	-0.9	-0.32	-0.51	0.31	-0.38	-0.33	-0.91	0.26	-0.56	-0.34	-0.58	-0.34	-0.42	0.75	-0.58	0.94	1.0

Click cells to compare fundamentals

If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Competition

Predict Gain Therapeutics

Based on the recorded statements, Gain Therapeutics has 718.74 K of outstending shares currently sold short by investors. This is 77.53% lower than that of the Biotechnology sector and 85.9% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 84.73% higher than that of the company.

Gain Number Of Shares Shorted Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gain Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gain Therapeutics could also be used in its relative valuation, which is a method of valuing Gain Therapeutics by comparing valuation metrics of similar companies.

Gain Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Gain Fundamentals

	Return On Equity	-1.89
	Return On Asset	-0.73
	Current Valuation	38.06 M
	Shares Outstanding	26.53 M
	Shares Owned By Insiders	5.09 %
	Shares Owned By Institutions	7.96 %
	Number Of Shares Shorted	718.74 K
	Price To Book	5.54 X
	Price To Sales	925.92 X
	Revenue	55.18 K
	Gross Profit	(7.66 M)
	EBITDA	(22.17 M)
	Net Income	(22.27 M)
	Cash And Equivalents	24.25 M
	Cash Per Share	2.04 X
	Total Debt	1.03 M
	Debt To Equity	0.05 %
	Current Ratio	7.58 X
	Book Value Per Share	0.78 X
	Cash Flow From Operations	(18.87 M)
	Short Ratio	1.65 X
	Earnings Per Share	(1.07) X
	Target Price	7.4
	Number Of Employees	29
	Beta	0.34
	Market Capitalization	49.34 M
	Total Asset	18.61 M
	Retained Earnings	(60.78 M)
	Working Capital	12.83 M
	Net Asset	18.61 M

About Gain Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Gain Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC